In a government letter published on July 27, the National Institute of Health and eight other national institutes wrote that they aim “to promote mechanistic research of therapeutic benefits of minor cannabinoids and terpenes in the cannabis plant.”
Published in the Journal of Clinical Psychiatry, the study involved 31 people aged between 12 and 25 who had been diagnosed with an anxiety disorder. All were given CBD capsules to take daily over twelve weeks.
Published in the journal JAMA Otolaryngology–Head & Neck Surgery, the study used data collected by the National Health and Nutrition Examination Survey (NHANES) to assess the association between cannabis use frequency and reports of sinonasal symptoms.
SC Labs is expanding. The Californian cannabis testing lab moved into Michigan and Colorado this year. How is it braving new frontiers when other labs are struggling with the one location? We asked the company’s new CEO, Jeff Journey, and co-founder Josh Wurzer to find out.
The microdosers in the study generally reported less depression, stress, and anxiety after one month of use, compared to their non-microdosing peers.
Analytical Cannabis caught up with Dr. Arora to discuss his podcast, his role as an advisor to cannabis and psychedelic businesses, and what the future holds for both sectors.